The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties

Barbara J. Caldarone, Neil E. Paterson, Jia Zhou, Daniela Brunner, Alan P. Kozikowski, Koen G C Westphal, Gerdien A H Korte-Bouws, Jolanda Prins, S. Mechiel Korte, Berend Olivier, Afshin Ghavami

Research output: Contribution to journalArticle

Abstract

Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin transporter are being developed as a new class of antidepressant that may have better efficacy and fewer side effects compared with traditional antidepressants. We describe a novel TRI, 2-[4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl]-1-(3- methylpiperidin-1-yl)-ethanone (JZAD-IV-22), that inhibits all three monoamine transporters with approximately equal potency in vitro. (+/-)-1-(3,4- dichlorophenyl)-3-azabicyclo-[3.1.0]hexane hydrochloride (DOV 216,303), a TRI shown to be an effective antidepressant in a clinical trial, shows reuptake inhibition similar to that of JZAD-IV-22 in vitro. Furthermore, both JZAD-IV-22 and DOV 216,303 increase levels of dopamine, norepinephrine, and serotonin in the mouse prefrontal cortex when administered by peripheral injection. JZAD-IV-22 and DOV 216,303 exhibited antidepressant-like efficacy in the mouse forced-swim and tail-suspension tests at doses that increased neurotransmitter levels. Because development of DAT inhibitors could be hindered by abuse liability, both JZAD-IV-22 and DOV 216,303 were compared in two assays that are markers of abuse potential. Both JZAD-IV-22 and DOV 216,303 partially substituted for cocaine in a drug discrimination assay in rats, and high doses of DOV 216,303 produced locomotor sensitization in mice. JZAD-IV-22 showed no evidence of sensitization at any dose tested. These results demonstrate that JZAD-IV-22 is a TRI with antidepressant-like activity similar to that of DOV 216,303. The striking feature that distinguishes the two TRIs is that locomotor sensitization, a common underlying feature of drugs of abuse, is seen with DOV 216,303 but is completely lacking in JZAD-IV-22. These findings may have implications for the potential for abuse liability in humans.

Original languageEnglish (US)
Pages (from-to)762-770
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume335
Issue number3
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Antidepressive Agents
Pharmacology
Dopamine Plasma Membrane Transport Proteins
2-(4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl)-1-(3-methylpiperidin-1-yl)-ethanone
Norepinephrine Plasma Membrane Transport Proteins
Hindlimb Suspension
1-(3,4-dichlorophenyl)-3-azabicyclo-(3.1.0)hexane hydrochloride
Serotonin Plasma Membrane Transport Proteins
Street Drugs
Prefrontal Cortex
Cocaine
Neurotransmitter Agents
Dopamine
Serotonin
Norepinephrine
Clinical Trials
Injections
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. / Caldarone, Barbara J.; Paterson, Neil E.; Zhou, Jia; Brunner, Daniela; Kozikowski, Alan P.; Westphal, Koen G C; Korte-Bouws, Gerdien A H; Prins, Jolanda; Korte, S. Mechiel; Olivier, Berend; Ghavami, Afshin.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 335, No. 3, 12.2010, p. 762-770.

Research output: Contribution to journalArticle

Caldarone, BJ, Paterson, NE, Zhou, J, Brunner, D, Kozikowski, AP, Westphal, KGC, Korte-Bouws, GAH, Prins, J, Korte, SM, Olivier, B & Ghavami, A 2010, 'The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties', Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 3, pp. 762-770. https://doi.org/10.1124/jpet.110.174011
Caldarone, Barbara J. ; Paterson, Neil E. ; Zhou, Jia ; Brunner, Daniela ; Kozikowski, Alan P. ; Westphal, Koen G C ; Korte-Bouws, Gerdien A H ; Prins, Jolanda ; Korte, S. Mechiel ; Olivier, Berend ; Ghavami, Afshin. / The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. In: Journal of Pharmacology and Experimental Therapeutics. 2010 ; Vol. 335, No. 3. pp. 762-770.
@article{baea9b284e134a058063fd30adf0aa93,
title = "The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties",
abstract = "Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin transporter are being developed as a new class of antidepressant that may have better efficacy and fewer side effects compared with traditional antidepressants. We describe a novel TRI, 2-[4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl]-1-(3- methylpiperidin-1-yl)-ethanone (JZAD-IV-22), that inhibits all three monoamine transporters with approximately equal potency in vitro. (+/-)-1-(3,4- dichlorophenyl)-3-azabicyclo-[3.1.0]hexane hydrochloride (DOV 216,303), a TRI shown to be an effective antidepressant in a clinical trial, shows reuptake inhibition similar to that of JZAD-IV-22 in vitro. Furthermore, both JZAD-IV-22 and DOV 216,303 increase levels of dopamine, norepinephrine, and serotonin in the mouse prefrontal cortex when administered by peripheral injection. JZAD-IV-22 and DOV 216,303 exhibited antidepressant-like efficacy in the mouse forced-swim and tail-suspension tests at doses that increased neurotransmitter levels. Because development of DAT inhibitors could be hindered by abuse liability, both JZAD-IV-22 and DOV 216,303 were compared in two assays that are markers of abuse potential. Both JZAD-IV-22 and DOV 216,303 partially substituted for cocaine in a drug discrimination assay in rats, and high doses of DOV 216,303 produced locomotor sensitization in mice. JZAD-IV-22 showed no evidence of sensitization at any dose tested. These results demonstrate that JZAD-IV-22 is a TRI with antidepressant-like activity similar to that of DOV 216,303. The striking feature that distinguishes the two TRIs is that locomotor sensitization, a common underlying feature of drugs of abuse, is seen with DOV 216,303 but is completely lacking in JZAD-IV-22. These findings may have implications for the potential for abuse liability in humans.",
author = "Caldarone, {Barbara J.} and Paterson, {Neil E.} and Jia Zhou and Daniela Brunner and Kozikowski, {Alan P.} and Westphal, {Koen G C} and Korte-Bouws, {Gerdien A H} and Jolanda Prins and Korte, {S. Mechiel} and Berend Olivier and Afshin Ghavami",
year = "2010",
month = "12",
doi = "10.1124/jpet.110.174011",
language = "English (US)",
volume = "335",
pages = "762--770",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties

AU - Caldarone, Barbara J.

AU - Paterson, Neil E.

AU - Zhou, Jia

AU - Brunner, Daniela

AU - Kozikowski, Alan P.

AU - Westphal, Koen G C

AU - Korte-Bouws, Gerdien A H

AU - Prins, Jolanda

AU - Korte, S. Mechiel

AU - Olivier, Berend

AU - Ghavami, Afshin

PY - 2010/12

Y1 - 2010/12

N2 - Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin transporter are being developed as a new class of antidepressant that may have better efficacy and fewer side effects compared with traditional antidepressants. We describe a novel TRI, 2-[4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl]-1-(3- methylpiperidin-1-yl)-ethanone (JZAD-IV-22), that inhibits all three monoamine transporters with approximately equal potency in vitro. (+/-)-1-(3,4- dichlorophenyl)-3-azabicyclo-[3.1.0]hexane hydrochloride (DOV 216,303), a TRI shown to be an effective antidepressant in a clinical trial, shows reuptake inhibition similar to that of JZAD-IV-22 in vitro. Furthermore, both JZAD-IV-22 and DOV 216,303 increase levels of dopamine, norepinephrine, and serotonin in the mouse prefrontal cortex when administered by peripheral injection. JZAD-IV-22 and DOV 216,303 exhibited antidepressant-like efficacy in the mouse forced-swim and tail-suspension tests at doses that increased neurotransmitter levels. Because development of DAT inhibitors could be hindered by abuse liability, both JZAD-IV-22 and DOV 216,303 were compared in two assays that are markers of abuse potential. Both JZAD-IV-22 and DOV 216,303 partially substituted for cocaine in a drug discrimination assay in rats, and high doses of DOV 216,303 produced locomotor sensitization in mice. JZAD-IV-22 showed no evidence of sensitization at any dose tested. These results demonstrate that JZAD-IV-22 is a TRI with antidepressant-like activity similar to that of DOV 216,303. The striking feature that distinguishes the two TRIs is that locomotor sensitization, a common underlying feature of drugs of abuse, is seen with DOV 216,303 but is completely lacking in JZAD-IV-22. These findings may have implications for the potential for abuse liability in humans.

AB - Triple reuptake inhibitors (TRIs) that block the dopamine transporter (DAT), norepinephrine transporter, and serotonin transporter are being developed as a new class of antidepressant that may have better efficacy and fewer side effects compared with traditional antidepressants. We describe a novel TRI, 2-[4-(4-chlorophenyl)-1-methylpiperidin-3-ylmethylsulfanyl]-1-(3- methylpiperidin-1-yl)-ethanone (JZAD-IV-22), that inhibits all three monoamine transporters with approximately equal potency in vitro. (+/-)-1-(3,4- dichlorophenyl)-3-azabicyclo-[3.1.0]hexane hydrochloride (DOV 216,303), a TRI shown to be an effective antidepressant in a clinical trial, shows reuptake inhibition similar to that of JZAD-IV-22 in vitro. Furthermore, both JZAD-IV-22 and DOV 216,303 increase levels of dopamine, norepinephrine, and serotonin in the mouse prefrontal cortex when administered by peripheral injection. JZAD-IV-22 and DOV 216,303 exhibited antidepressant-like efficacy in the mouse forced-swim and tail-suspension tests at doses that increased neurotransmitter levels. Because development of DAT inhibitors could be hindered by abuse liability, both JZAD-IV-22 and DOV 216,303 were compared in two assays that are markers of abuse potential. Both JZAD-IV-22 and DOV 216,303 partially substituted for cocaine in a drug discrimination assay in rats, and high doses of DOV 216,303 produced locomotor sensitization in mice. JZAD-IV-22 showed no evidence of sensitization at any dose tested. These results demonstrate that JZAD-IV-22 is a TRI with antidepressant-like activity similar to that of DOV 216,303. The striking feature that distinguishes the two TRIs is that locomotor sensitization, a common underlying feature of drugs of abuse, is seen with DOV 216,303 but is completely lacking in JZAD-IV-22. These findings may have implications for the potential for abuse liability in humans.

UR - http://www.scopus.com/inward/record.url?scp=78649618505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649618505&partnerID=8YFLogxK

U2 - 10.1124/jpet.110.174011

DO - 10.1124/jpet.110.174011

M3 - Article

C2 - 20864506

AN - SCOPUS:78649618505

VL - 335

SP - 762

EP - 770

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -